We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.225 | 0.67% | 33.825 | 494,358 | 16:35:20 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 33.50 | 34.15 | 35.95 | 33.50 | 35.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 3.1M | -6.51M | -0.0216 | -15.51 | 101.29M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:28:10 | O | 40,000 | 34.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/7/2024 | 14:13 | UK RNS | Futura Medical PLC Total Voting Rights |
| 01/7/2024 | 07:00 | UK RNS | Futura Medical PLC Nominated Adviser and Joint Broker |
| 20/6/2024 | 20:02 | ALNC |  EARNINGS AND TRADING: Lords trading in line; Time Out trading ahead |
| 20/6/2024 | 16:12 | UK RNS | Futura Medical PLC Result of AGM |
| 20/6/2024 | 07:00 | UK RNS | Futura Medical PLC AGM Statement |
| 31/5/2024 | 07:00 | UK RNS | Futura Medical PLC Block Listing Six Monthly Review |
| 24/5/2024 | 07:00 | UK RNS | Futura Medical PLC Notice of AGM and availability of Annual Report |
| 29/4/2024 | 07:00 | UK RNS | Futura Medical PLC Directors’ / PDMR Dealing and Grant of Options |
| 10/4/2024 | 10:49 | ALNC | Futura Medical hails results as erectile dysfunction drug drives sales |
| 10/4/2024 | 07:00 | UK RNS | Futura Medical PLC Results for the Year ended 31 December 2023 |
Futura Medical (FUM) Share Charts1 Year Futura Medical Chart |
|
1 Month Futura Medical Chart |
Intraday Futura Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 11:36 | FUTURA a winner for 2015 | 21,406 |
| 05/6/2024 | 19:50 | Berenberg upgrading Haleon | - |
| 30/5/2024 | 10:36 | FUM this ones bound to rise! | 94 |
| 31/10/2023 | 15:48 | fum value | 1 |
| 02/7/2023 | 10:15 | Quiet on here | 34 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:28:11 | 34.00 | 40,000 | 13,600.00 | O |
| 2024-07-26 15:27:14 | 33.54 | 907 | 304.20 | O |
| 2024-07-26 15:25:53 | 33.50 | 7 | 2.35 | AT |
| 2024-07-26 15:24:18 | 34.00 | 20,009 | 6,803.06 | O |
| 2024-07-26 15:11:28 | 33.50 | 116 | 38.86 | AT |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Futura Medical Daily Update Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 33.60p.Futura Medical currently has 301,449,541 shares in issue. The market capitalisation of Futura Medical is £100,985,596. Futura Medical has a price to earnings ratio (PE ratio) of -15.51. This morning FUM shares opened at 35p |
Posted at 16/6/2024 14:39 by mdi ‘I was referring to RNS from 2023, update in 2024 uses amended wording’April 2024 results Still the exact same wording being used as 2023. Clearly saying will commercialise if its the ‘only clinically proven gel’ ‘Haleon will commercialise Eroxon® in the USA as the first and only clinically proven gel treatment for ED’ So again you are wrong and yes unlike shareholders the BOD get paid to ‘chill’ with upfront cash salaries, cash bonuses and share options. Yet still they own only less then even 1% of the shares. With no sign of them dipping into their own pockets and piling into buy more shares at this supposed bargain share price? It distinctly looks like the BOD don’t want to ‘chill’ in the same sinking boat as the ‘layman’ shareholders. And actually the ‘longer the timelines extend out’ and if revenues from this placebo gel product are indeed sustainable and if no consumer lawsuits. Then its more likely a similar non medicated hydroalcoholic gel product will be launched by the likes of Reckitt under their Durex or KY brands. Not as if that didn’t happen before with all the other Futura products? ˜a company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially immediately’ De Novo authorization will also allow subsequent devices of the same type and intended use to come to the market through the 510k pathway, which could enable the devices to get on the market faster the average time to issue a decision in 2021 was 147 days according to FDA data. For the year up to the end of September 2022, 85 percent of 510(k) applications were issued with a Substantially Equivalent decision from the FDA. A Substantially Equivalent decision means the product has regulatory approval to be sold in the US market. ˜The vast majority of our FDA 510K clients generally spend in the range of $20,000-$30,000 to have their product or device prepared and reviewed before the actual FDA 510k submission process One of the positive sides to seeking a FDA 510K approval for a new medical product, whether tested or untested, is that if there is already a similar FDA approved product being marketed, then the FDA will have to approve any new products that are almost the same as the product that is already FDA 510 K approved and have under gone all required testing, documentation, and registration processesâ€&tra |
Posted at 10/6/2024 15:29 by takeiteasy The company share price you are comparing FUM that you are using to beat up FUM has yet to make any sales - it is a development pharma in research validation phases - using a totally different technology so we have zero idea what sales are possible at this stage. Do try to provide better context etc etc. |
Posted at 09/6/2024 07:31 by takeiteasy Please try not to treat fellow investors as fools here. The following are publicly known:Amazon sales dropped 75% from 4k to 1k after the advertising campaigns quietened down FUM failed to provide Q1 2024 sales - you can read a lot into this either way i.e. do not want to alert rivals things are booming or things are simply only progressing steadily USA launch is being delayed with no sufficient explanation (for me anyway) why FUM do have some form of patent in some parts of the globe - this is untested in law but can be used to backup the analyst views Competitors will be waiting eagerly I suspect on repeat business numbers to see whether it is worth entering the market - if barriers to entry are as low as you think there is no benefit to them trying to jump the gun here as it will not take long to jump in when they want I repeat again, you do not need to agonise I think that the brokers are baking in more positivity that you see here, the market price is discounting 70% of their positivity and that is all we need to know fwiw. You seem to want to make out there is some massive issue over the who way FUM is being assessed. Assumptions if stated are simply assumptions and we will all hold our own view. For me, I like the opportunity but the failure to present q1 2024 sales data has swung the argument entirely. This view is based on my assumptions of what I think may be going on and I may be wrong. nai/dyor etc - but please stop the endless moaning about the firm. it is adding not a single bit of value to anyone. No one is being misled etc etc. |
Posted at 09/6/2024 00:07 by mdi ‘Very unclear size of the potential market anyway’‘no evidence out there on competitor activity’ The broker headline peak estimates appear very clearly in order to be able to substantiate the price targets. What is ‘unclear&rsquo ‘estimate that the US rollout will improve group organic sales by on average 0.8pp in its first five years (2025-29)’ which seemed to based on what management claimed happened in Belgium and UK and a supposed ‘20%’ ‘We note that there are already encouraging signs from the rollout of Eroxon in the UK and Belgium, with the brand gaining 20% share in its first 12 months’ But according to Ceuta ‘Online provided the majority of sales’ for Eroxon. So that is how Futura were able come up with the headline market share they touted in the RNS that Eroxon supposedly captured in the early days of launching in UK and Belgium of ‘c. 20% market share of approved ED treatments’. So Eroxon actually just captured 20% of a smalll online market of approved ED treatments ie mainly online sales of other medical devices which are also all ‘approved ED treatments. But which mostly excludes the online sale of drugs like Viagra, Cialis etc. As online sales are mostly an ‘option not open to pharmacy’ (P) classified medicines like sildenafil and tadalafil, which can only be dispensed after consultation with a pharmacy professional’ And what is also known is the sales in the UK and Belgium collapsed after the launch hype. So the questionable 20% share was also not even sustainable. And the fact remains that the £1.7m revenue in April/May was followed by only £1.4m in the following 6 months And if the size of the market for non medicated hydroalcoholic gel is indeed sustainable in any way and anywhere near what some of the brokers are estimating based on the highly questionable assumptions. Then why wouldn’t there be substantial competitor activity when it only costs $30k and takes less then 6 months to launch an equivalent gel in a supposedly lucrative market. Researchers found that, over 14 weeks, men who were randomly assigned to take Viagra plus testosterone gel did no better than those given the drug plus a hormone-free placebo gel. Overall, men in both groups responded On average, the men's score on a standard set of erectile dysfunction questions increased by about 8 points removing them up to the "mild" erectile dysfunction category. And there was no substantial difference between men who used the testosterone gel and those who used the placebo Auxilium Pharmaceuticals provided the testosterone gel, and Pfizer supplied the Viagra Testim® (testosterone gel) is a clear to translucent hydroalcoholic topical gel Inactive ingredients in Testim are purified water, pentadecalactone, carbopol, acrylates, propylene glycol, glycerin, polyethylene glycol, ethanol |
Posted at 08/6/2024 16:57 by takeiteasy The share price is about a 70% haircut to the broker target price - everyone I would imagine is more than comfortable accepting the risks that you raise in ending up at such a considerable difference.Just try to come up with something different - we got the message a very long time ago. You desparately want the broker to state your view but it is not going to happen atm with no evidence out there on competitor activity. Very unclear size of the potential market anyway. Any broker estimate is that an estimate when the market is so immature at this stage. Chill. |
Posted at 05/6/2024 20:05 by keifer derrin [...]Berenberg initiated coverage of consumer health company Haleon on Wednesday with a ‘buy’ rating and 407p price target. The bank said its investment case is based in part on the US launch of Eroxon, which it expects to drive better-than-expected organic sales growth of 5.8% in 2025 (consensus 4.9%). Berenberg said the opportunity from the US launch of Eroxon - the first-ever over-the-counter erectile dysfunction (ED) topical cream - is "substantial". It noted that among men of all ages, 20% suffer from ED, but the condition is more pronounced in older age groups, as 50% of over 40s experience ED. "Importantly, 80% of men who suffer from ED are not taking any treatment, meaning the addressable market for Eroxon is significant," it said. "We conservatively estimate that the US rollout will improve group organic sales by on average 0.8pp in its first five years (2025-29). We note that there are already encouraging signs from the rollout of Eroxon in the UK and Belgium, with the brand gaining 20% share in its first 12 months." The bank’s investment case is also based on Haleon’s exposure to attractive categories that it expects to grow 4.6% in the medium term, which is above Berenberg’s forecast sector average of 4.1%; and the stock trading on a valuation discount of 17% to key household and personal care (HPC) peers. Berenberg noted that Haleon trades on a 12-month forward price-to-earnings of 17.3x. "For a company offering 5.6% medium-term organic sales growth, we view the stock as mispriced," it said. "We believe that a re-rating will be driven by continued delivery of superior top-line sales growth, attractive gross margins, positive surprises and earnings upgrades on the back of the US launch of Eroxon within the next 12 months. Further prescription-to-OTC (Rx-to-OTC) switches will support additional growth in the medium term." At 1340 BST, the shares were up 1.3% at 326.80p. |
Posted at 04/5/2024 17:24 by mdi And at 30 June 2023 there is also now close to £65 million in retained losses in Futura. So If Eroxon has been more or less fully licensed out so as the distributors control its future. And all of the other Futura products have now disappeared. Why would the large shareholders be willing to continue to pay the Directors well over £1m per year to be effectively doing nothing? Never mind adding in the annual costs of being AIM market listed. And if, as they say, they dont need to raise any more money. Even at this current £100m paper market valuation from shareholders. Then why even waste money on being listed? Did they not claim in the recent Q&A presentation that they were starting to get some institutional interest? Yet the share price even with all the supposedly positive future is still falling over the last few weeks and months. |
Posted at 04/5/2024 16:53 by mdi How much has the Futura market cap declined now since June of last year? I read that the major shareholders average price is still well below even the current share price. So even even if the share price declines further they will still be in profit. So will Directors on many of their 7p and 15p share options if the share price even falls another 40% to the low 20’s. That would still be a Market Cap of nearly £70mHard to tell which is falling faster now. Eroxon sales after the hype or the Futura market cap after the hype. But the fact remains that the £1.7m revenue in April/May was followed by only £1.4m in the following 6 months. New market launches being hyped and staggered may well help short term to prop up the obvious declining sales. |
Posted at 12/4/2024 12:21 by takeiteasy Total and complete capitulation it seems...I wonder where Haleon are at with all this. They have given this project a very high profile and will manage every risk for success - mindful that durex and the rest will jump at the chance to compete at a drop of a hat if they think there is a real market out there. If I was Haleon I would take the following steps to manage risks: Wait until sufficient air cover is in place with enough patents Give no information out whatsoever on repeat purchasing - so no one can guess the market opportunity Establish sufficient manufacturing scale in USA for go live Get some follow up female products ready so it appears a product suite can be established rather than a one hit wonder Give a sense go live is a long way off to form the impression for the oppo there is no rush to bring forward rival offerings If that is the plan, FUM knows it will trash the share price as it has done so a payment has to be made to compensate near term... This is my only way of understanding what is going on - if anyone else can see the wood from the trees better - happy days :) dyor and no advice and imvho |
Posted at 06/2/2024 15:47 by keifer derrin Dermsys is the base product and in the early days, FUM added a drug to dermasys for ED.Unusally for the Phase III trail the authorities made FUM use dermasys as the plecebo. Normally they would have used another inert gel product When the test was released it appeared that dermasys worked the same as with the added drug. Which was it worked in 60% of males. Hence why it appears that it was the same as a placebo As they didn't need to use the added "drug" it allowed FUM to proceed down the current route without having to do any extra tests. Although the FDA made FUM do some other testing on African Americans and that it worked over a period of time. From this test FUM also found that the longer they used the product the better the erection (edited to add extra to post |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
